Skip to main content
Fig. 2 | BMC Complementary Medicine and Therapies

Fig. 2

From: In vivo and in vitro safety evaluation of fermented Citrus sunki peel extract: acute and 90-day repeated oral toxicity studies with genotoxicity assessment

Fig. 2

Absence of reverse mutation capacity in fermented C. sunki peel extract. Five bacterial tester strains (4 histidine auxotrophs S. typhimurium TA98, TA100, TA1535 and TA1537 and 1 tryptophan auxotroph E. coli WP2(uvrA)) were employed to assess reverse mutation capacity of fermented C. sunki peel extract (FCPE). Treatment of the tester strains with increasing doses of FCPE (gray bars; 312.5, 625, 1250, 2500 and 5000 μg/plate) resulted in the similar numbers of revertant colonies to the vehicle control (white bars) in the absence (a) and presence (b) of the S-9 factor mediated metabolic activation, while significant increase in the colony number by positive controls (black bars). P1; 10 μg/plate 2-nitrofluroene, P2; 5 μg/plate sodium azide, P3; 0.5 μg/plate sodium azide, P4; 80 μg/plate 9-aminoacridine, P5; 0.5 μg/plate mitomycin C, and P6; 2-aminoanthracene. *; p < 0.05 by one-way ANOVA followed by Tukey’s HSD multiple comparison test

Back to article page